H.R. 5894 — Introduced in House

I 116th CONGRESS 2d Session H. R. 5894 IN THE HOUSE OF REPRESENTATIVES February 13, 2020Ms. Davids of Kansas (for herself, Ms. Slotkin, and Ms. Finkenauer) introduced the following bill; which was referred to the Committee on Energy and Commerce A BILL To direct the Secretary of Health and Human Services to issue guidance requiring the list prices of drugs to be included in advertisements for such drugs. 1. Short title This Act may be cited as the Transparency in Prescription Drug Advertising Act. 2. Pricing transparency in drug advertising (a) In general Not later than one year after the date of enactment of this Act, the Secretary of Health and Human Services, in consultation with the Commissioner of Food and Drugs and the Administrator of the Centers for Medicare & Medicaid Services, shall issue department-wide guidance requiring the list prices of drugs to be included, as appropriate, in all advertising of drugs, including by means of television, newspapers, the internet, or other media. (b) Enforcement; consistency The guidance under subsection (a)— (1) shall include appropriate enforcement mechanisms for failure to make disclosures in accordance with the guidance; and (2) should be consistent with the regulation of the Centers for Medicare & Medicaid Services related to drug pricing transparency.